PLSE
Signal
Leaning Bearish11!1
Price
1
Move-9.41%Selling pressure
Volume
1
Volume1.8× avgHeavy volume
Technical
1
RSIRSI 79Overbought
Next earnings: Aug 11, 2026
ANALYST COVERAGE4 analysts
BUY
+22.2%upside to target
Buy
250%
Hold
250%
2 Buy (50%)2 Hold (50%)0 Sell (0%)
Full report →
PRICE
Prev Close
27.10
Open
26.15
Day Range23.74 – 26.80
23.74
26.80
52W Range12.56 – 27.98
12.56
27.98
78% of range
VOLUME & SIZE
Avg Volume
322.2K
FUNDAMENTALS
P/E Ratio
-22.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.38
Market-like
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 115 days
Sep 9
Key MetricsTTM
Market Cap$1.70B
Revenue TTM$751.0K
Net Income TTM-$74.57M
Free Cash Flow-$55.50M
Gross Margin-91.1%
Operating Margin-10392.1%
Net Margin-9929.0%
Return on Equity-86.7%
Return on Assets-91.4%
Debt / Equity0.11
Current Ratio7.26
EPS TTM$-1.10

PLSE News

About

pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and

Industry
Surgical and Medical Instrument Manufacturing
David KenigsbergChief Medical Officer
Liane TeplitskyChief Operating Officer
Gansevoort DunningtonChief Medical Officer
Niv AdChief Science Officer of Cardiac Surgery
Darrin R. UeckerChief Technology Officer & Director
David DanitzSenior Vice President of Engineering
Edison ManuelVice President of Operations
Jon SkinnerChief Financial Officer
Kenneth StrattonGeneral Counsel & Corporate Secretary
Mitchell E. LevinsonChief Strategy Officer
Paul Arthur LaViolettePresident, Chief Executive Officer & Co-Chairman of the Board
Steven T. WeberVice President of Accounting, Principal Accounting Officer & Global Corporate Controller
Patty PerlaVice President of Human Resources